TheraQuest Presents TQ-1015 Opioid Inflammatory Pain Results
at the American Pain Society Meeting
Blue Bell, PA – April 1, 2005/ PR Newswire/-- TheraQuest
Biosciences, a development stage pain management company has
unveiled new results from TQ-1015, its potent abuse deterrent
opioid agonist at the American Pain Society Annual Scientific
Meeting in Boston. The study evaluated the effects of TQ-1015
in inflammatory pain against mechanical allodynia and thermal
hyperalgesia and compared its potency with morphine.
Michael Ossipov, PhD, Associate Professor in the Department
of Pharmacology, University of Arizona College of Medicine
and a noted expert in analgesic pharmacology stated “TQ-1015
produced dose-dependent reversal of tactile hyperesthesia and
thermal hyperalgesia. The potency of TQ-1015 remained constant
over the time-course of the study. Importantly, TQ-1015 retained
its antinociceptive potency in the presence of inflammation.
These results indicate that TQ-1015 is active against increased
pain states associated with inflammation. It is consistently
more potent than morphine, with a high degree of efficacy.”
Najib Babul, PharmD, President and Chief Executive Officer
of TheraQuest stated, "TheraQuest is pleased to be presenting
peer-review data from TQ-1015 at the American Pain Society,
a premiere scientific venue which brings together basic scientists,
clinical scientists and clinicians interested in the field
of pain.”
About TQ-1015
TQ-1015 is being developed for the treatment of chronic cancer
and non-cancer pain. It is a once-a-day sustained release opioid
analgesic in a proprietary, abuse deterrent drug delivery system.
It cannot be crushed for inhalation or obtaining rapid euphoria.
It is also exceedingly difficult for I.V. abusers to extract
the active drug from the formulation using common solvents.
TQ-1015 is significantly more potent than current therapies
and it has a lower side effect profile than other opioids.
The target population includes patients with moderate to severe
chronic cancer and non-cancer pain. TQ-1015 will compete in
the same market segment as MS Contin®, OxyContin®,
Duragesic® and Palladone™.
About TheraQuest Biosciences
TheraQuest Biosciences, LLC is a private, development-stage
pain management company building a diversified portfolio
of pharmaceutical products to address a critical area of
unmet medical need. Despite their limitations, current treatments
for acute and chronic pain yield worldwide sales in excess
of $25 billion. The TheraQuest team has contributed to the
development of numerous analgesics approved in the U.S. over
the past 20 years. TheraQuest’s strategy is to use
its expertise to identify, develop and commercialize product
candidates with strong market potential that have lower development
costs and reduced regulatory risk than new chemical entities.
TheraQuest is headquartered in Blue Bell, Pennsylvania.
TheraQuest is funded in part by BioAdvance, the Biotechnology
Greenhouse of Southeastern Pennsylvania and Ben Franklin Technology
Partners of Southeastern Pennsylvania. Additional information
is available at www.theraquestinc.com.
|
